µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º *SkUkqP9z
s>sIji
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ COS(pfC
(]'Q!MjGa
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) />fP )56*
uM0!,~&9|
1. ICAM-1 _E5%Px5>L
4XL*e+UfJ
2. interleukin 12(IL-12) ld1t1'I'
o/I <)sa
3. tumor infiltrating lymphocyte '<
OB
j
&]~z-0`$!
4. TCR/CD3 complex ^RkHdA
Kb0O
auW
5. hematopoietin receptor family b5YjhRimS
qE6:`f
6. individual idiotype(IdI) 8
?'
]W\)
hCO*gtA)M
7. integrin zypZ3g{vz
9vL`|`Vau
8. colony-stimulatory factor (CSF) 7Z>u|L($m
]?,47,[<
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© IS7g{:}=p
"}DuAs
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? ~Dr/+h:^\
zW%-Z6%D
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ ?/"@WP9
MxxY MR
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ\Ja%u"DA
EF0{o_
4. ¼òÊö¿¹ÔÌá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ HKP\`KBCj
3a#637%
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) 6+IOJtj
8E/$nRfOd
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔÀí¡£ [8Ub#<]]
{a_=4a
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) =(*Eh=Pw
(|ga#%
iI
3. immunoglobulin superfamily (IgSF) <
PW*vo9v
? $pGG
4. selectin ^/R@bp#
<
*%ZfE,bu8<
5. anti-idiotypic antibody (¦ÁId) ix^:qw;
0"u*K n
6. major histocompatibility complex(MHC) 'm}~
B/E1nBobC
7. immunotolerance ekI1j%fO
*|$s0ga C
8. biological reponse modifier(BRM) <3HW!7Ad1
ezwcOYMXK
9. immune reponse gene (Ir gene) 3`#sXt9C
ErB6fl
10. reshaped antibody (or reconstituted antibody) H)
q9.Jg
D8`,PXtV
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© M0c"wi@S_
nImRU.;P
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ "5XD+qi
!bH-(K{S6
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? u9mMkzgSkP
d^]wqn pf
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ X@x:
F|/P
"793R^Tz
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? 9]NsWd^^
LfOGq%&
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ |V!A!tB
{!^HG+
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? .RJvu$U2j
s_`wLQ7e
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ An]*J|nFIY
pPQ]#v
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ 2Y 6/,W
)}G
HG#D{
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔÀíºÍ½á¹û²â¶¨? :Oq!.uO
7
hnTHL
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ .^JID~<?#
|C>Yd*E,C
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: VJ_E]}H
\8Blq5n-O*
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: "]MF =-v
D*D83z OzN
̉񧄤 S'E6#
hC6$>tl
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© p' /$)klt
d8]6<\g
1. CD8 n4Q!lJ
[]LNNO],X
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) m?<C\&)6x
d6hWmZVC
3. immunoglobulin fold(Ig fold) (''`Ce
B*D`KA
4. cadherin (Ca-dependent cell adhesion moleculers) EWqKd/
I9>1WT<Yy
5. idiotype-anti-idiotypic antibody immune network theory ZB
~D_S
N{Is
2Ia
6. HLA class II antigen :_Ng`b/
JN3Oe5yB2@
7. complementarity-determining region (CDR) p(Qm\g<
QKOo
#7
8. perforin(or pore-forming protein ,PFP) lZ_i~;u4@v
GhpH7%s
9. high affinity IL-2 receptor PJ
#uYM
- }
Z
10. artificial active immunization t~@TUTbx
26\1tOj Np
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Y%wF;I1x
!vett4C* K
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠWb*d`hzQ}
mH}AVje{
`
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 6Ajiz_~U
bLNQ%=FjO
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ Wigm`A=,r
X8*q[@$
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ BH
FWig*{
t0?BU~f
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔÀí¡£ ~'T]B{.+J
`9$?g|
rB
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? *M KVm)Iv
Vw)
\#6FL
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ Ye(0'*-jyc
e#W@ep|n
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ gk]r:p<